Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Epileptic Seizures in Multiple Sclerosis: A Population-Based Survey in Iran Publisher Pubmed



Etemadifar M2 ; Abtahi SH2, 3, 4 ; Roomizadeh P1, 3
Authors
Show Affiliations
Authors Affiliations
  1. 1. Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Neurology, Medical School, Isfahan University of Medical Sciences, Isfahan, Iran
  3. 3. Medical Students Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  4. 4. Isfahan, 81448-14581, SHARNOS Co. No. 9, Boroomand. Seyed-Alikhan, Chaharbagh Ab, Iran

Source: Acta Neurologica Belgica Published:2013


Abstract

No large population-based survey has until now been carried out on the linkage of epilepsy (EP) and multiple sclerosis (MS) either in the middle-east or in Asia. In this retrospective population-based study (April 2003 to July 2010) on the total Isfahan cohort of 3,522 Iranian MS patients, we looked for EP/MS patients and compared their features with 1,665 non-EP/MS cases. We identified 105 cases, though, 24 were excluded for an implausible EP/MS link. Among 81 (2.3 %) eligible cases, EP occurred (1) within a mean duration of 5.6 ± 5.4 years after the development of MS in 64 cases (79 %); (2) at MS onset as the presenting symptom in five cases (6.2 %); and, (3) by a mean duration of 4.3 ± 4.3 years prior to onset of MS in 12 patients (14.8 %). The overall mean ages at MS onset and at the first seizure episode were 28.5 ± 11.2 years and 32.5 ± 14.0 years, respectively. Regarding the age at onset of MS, 12.3 % of EP/MS patients were classified as early-onset; 81.5 % as adult-onset; and 6.2 % as late-onset. Such frequencies were statistically different (P < 0.0001) from those of the 1,665 control non-EP/MS patients (5.9; 93.0 and 1.1 %, respectively). Regarding the pattern of MS, EP/MS patients were classified as relapsing-remitting, secondary progressive, and primary progressive in 60.5, 25.9, and 13.6 %, respectively. This configuration differed (P < 0.0001) from that of non-EP patients (87.9; 6.3 and 5.7 %, respectively). Our results are suggestive of differences between EP/MS and non-EP/MS cases as regards the proportion of MS patterns and age-at-onset classifications. © 2012 Belgian Neurological Society.
Related Docs
View other Related Docs
1. Seizure in Iranian Patients With Multiple Sclerosis, Journal of Research in Medical Sciences (2013)
2. Prevalence of Seizure/Epilepsy in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2021)
3. Seizure Characteristics in Multiple Sclerosis Patients, Journal of Research in Medical Sciences (2013)
4. Epileptic Seizures in Early-Onset Multiple Sclerosis, Archives of Iranian Medicine (2012)
5. Does Early-Onset Multiple Sclerosis Differ From Adult-Onset Form in Iranian People, Journal of Research in Medical Sciences (2010)
6. Clinical Characteristics and Disability Progression of Early-And Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis, Journal of Clinical Medicine (2020)
7. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
8. Prevalence and Incidence of Multiple Sclerosis in Isfahan, Iran Between 1996 and 2021: A Population-Based Study, Multiple Sclerosis and Related Disorders (2024)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (82)
Masoud Etemadifar (59)
Other Related Docs
9. Sharp Increase in the Incidence and Prevalence of Multiple Sclerosis in Isfahan, Iran, Multiple Sclerosis Journal (2011)
10. Early-Onset Multiple Sclerosis in Isfahan, Iran: Report of the Demographic and Clinical Features of 221 Patients, Journal of Child Neurology (2016)
11. Incidence and Prevalence of Multiple Sclerosis in Persian Gulf Area: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2020)
12. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
13. Management of Seizures in Patients With Multiple Sclerosis; an Iranian Consensus, Epilepsy and Behavior (2019)
14. Eeg Biofeedback for Treatment of Psychogenic Non-Epileptic Seizures (Pnes) in Multiple Sclerosis: A Case Report, Applied Psychophysiology Biofeedback (2021)
15. Jacksonian Seizure As the Relapse Symptom of Multiple Sclerosis, Journal of Research in Medical Sciences (2013)
16. Epidemiological and Clinical Features of Pediatric-Onset Multiple Sclerosis: A Population-Based Study in Isfahan, Iran, Between 1997-2020, Current Journal of Neurology (2021)
17. Epidemiology of Multiple Sclerosis in Iran: A Systematic Review, European Neurology (2013)
18. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran, European Neurology (2014)
19. The Effect of Fampridine on the Risk of Seizure in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)
20. Lateonset Multiple Sclerosis in Isfahan, Iran, Archives of Iranian Medicine (2012)
21. Better Prognosis of Multiple Sclerosis in Patients Who Experienced a Full-Term Pregnancy, European Neurology (2012)
22. Ongoing Increase in Incidence and Prevalence of Multiple Sclerosis in South-Eastern Iran: A Three Decade Study, Multiple Sclerosis and Related Disorders (2023)
23. Prevalence of Multiple Sclerosis in Isfahan, Iran, Neuroepidemiology (2006)
24. Epidemiology of Familial Multiple Sclerosis in Iran: A National Registry-Based Study, BMC Neurology (2022)
25. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
26. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
27. Demographic and Clinical Characteristics of Familial and Sporadic Multiple Sclerosis Patients, International Journal of Preventive Medicine (2023)
28. Prognostic Indicators in Pediatric Clinically Isolated Syndrome, Annals of Neurology (2017)
29. The Kurtzke Edss Rank Stability Increases 4 Years After the Onset of Multiple Sclerosis: Results From the Msbase Registry, Journal of Neurology, Neurosurgery and Psychiatry (2012)
30. Childhood-Onset Multiple Sclerosis: Report of 82 Patients From Isfahan, Iran, Archives of Iranian Medicine (2007)
31. Multiple Sclerosis Epidemiology in Asia and Oceania; a Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
32. Interferon-Beta in Pediatric Multiple Sclerosis Patients: Safety in Short-Term Prescription, Acta Medica Iranica (2012)
33. Multiple Sclerosis: Pathophysiology, Clinical Features, Diagnosis, and Management, Neuroinflammation (2011)
34. Risk Factors of Multiple Sclerosis and Their Relation With Disease Severity: A Cross-Sectional Study From Iran, Archives of Iranian Medicine (2016)
35. Clinical and Demographical Characteristics of Primary Progressive Multiple Sclerosis in Isfahan, Iran, European Journal of Neurology (2007)
36. The Prevalence of Multiple Sclerosis (Ms) in Oceania, a Systematic Review, and Meta-Analysis, Neurological Sciences (2024)
37. Characteristics of Familial Multiple Sclerosis in Isfahan, Iran: A Cross-Sectional Study, Neurology Asia (2014)
38. Pediatric Multiple Sclerosis With Primary Progressive Course-Report of a Retrospective Cohort Study in Iran, Neuropediatrics (2013)
39. A National Registry-Based Study of Ethnic Differences in People With Multiple Sclerosis in Iran, Clinical Neurology and Neurosurgery (2024)
40. Risk Factors of Early Onset of Ms in Women in Reproductive Age Period: Survival Analysis Approach, Archives of Women's Mental Health (2016)
41. Male Sex Is Independently Associated With Faster Disability Accumulation in Relapse-Onset Ms But Not in Primary Progressive Ms, PLoS ONE (2015)
42. Prevalence of Multiple Sclerosis (Ms) in Iran: A Systematic Review and Meta-Analysis, Neurological Sciences (2022)
43. Prevalence of Familial Multiple Sclerosis in Isfahan, Iran, Journal of Isfahan Medical School (2011)
44. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
45. Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018, CNS Drugs (2021)
46. Working Memory Dysfunction Differs Between Secondary Progressive and Relapsing Multiple Sclerosis: Effects of Clinical Phenotype, Age, Disease Duration, and Disability, Multiple Sclerosis and Related Disorders (2023)
47. Multiple Sclerosis Is Associated With Worse Covid-19 Outcomes Compared to the General Population: A Population-Based Study, Multiple Sclerosis and Related Disorders (2023)
48. The Global Prevalence of Familial Multiple Sclerosis: An Updated Systematic Review and Meta-Analysis, BMC Neurology (2021)
49. Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years, Neurology (2021)
50. Prevalence of Cognitive Impairment (Ci) in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2024)